GlaxoSmithKline plc (GSK) |
|
44.5 0.17 (0.38%)
|
11-19 16:01 |
|
Open: |
44.63 |
Pre. Close: |
44.33 |
|
High:
|
44.7 |
Low:
|
44.29 |
|
Volume:
|
2,155,577 |
Market Cap:
|
110909M |
|
|
|
|
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
44.744 - 44.916 |
44.916 - 45.088 |
|
Low:
|
43.829 - 44.04 |
44.04 - 44.25 |
|
Close:
|
44.155 - 44.473 |
44.473 - 44.791 |
|
Technical analysis |
as of: 2019-11-19 4:26:50 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 53.74 One year: 62.77 |
| Support: |
Support1: 43.45  Support2: 41.87 |
| Resistance: |
Resistance1: 46.01 Resistance2: 53.74 |
| Pivot: |
44.61  |
| Moving Average: |
MA(5): 44.28 MA(20): 44.47
MA(100): 41.97 MA(250): 40.67 |
| MACD: |
MACD(12,26): 0.39 Signal(9): 0.52 |
| Stochastic oscillator: |
%K(14,3): 34.36 %D(3): 29.33 |
| RSI: |
RSI(14): 57.35 |
| 52-week: |
High: 46.01 Low: 36.41 Change(%): 9.5 |
| Average Vol(K): |
3-Month: 242289 10-Days: 208566 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.GSK has closed above bottom band by 44.4%. Bollinger Bands are 0.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-11-15
Outlook on the World Market for Anemia & Other Blood Disorder Drugs, 2020-2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anemia And Other Blood Disorder Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global anemia and other blood disorder drugs market was valued at about $19.7 billion in 2018 and is expected to grow to $29.37 billion at a CAGR of 10.5% through 2022. Major players in the market are Amgen, GlaxoSmithKline, Akebia therapeutics, Bayer and Pfizer. North America was the largest region in the anemia and other blood disorder
2019-11-13
Bharat Biotech launches anti-rabies vaccine ChiroRab
Seven months after vaccine manufacturer Bharat Biotech acquired Chiron Behring vaccines Pvt Ltd from GlaxoSmithKline (GSK), it launched ChiroRab, an anti-rabies vaccine, thereby becoming the largest rabies shot manufacturer in the world. Earlier marketed under the trade name Rabipur, ChiroRab has been evaluated in over 25 controlled clinical trials in 5 countries in more than 7000 subjects. “I am proud to introduce the ChiroRab,” said Krishna Ella, CMD, Bharat biotech International Ltd. The health ministry was recently in news following concerns of dwindling anti-rabies supplies and the relaunch of the vaccine is expected to curb the shortage of the vaccine. “In our ongoing commitment to address the supply shortages of rabies vaccine, we are making additional investments to increase production capacities to over 15 million doses annually,” added Ella. "The launch of the vaccine is 'very timely' for a country like India,” said Renu Swarup, secretary, Department of Biotechnology. “The highest success story in product development is vaccine development.
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: New York Stock Exchange |
| Sector: Healthcare |
| Industry: Drug Manufacturers - Major |
| Shares Out. (M) |
2490.00 |
| Shares Float (M) |
2450.00 |
|
% Held by Insiders
|
0.01 |
|
% Held by Institutions
|
11.00 |
|
Shares Short (K)
|
6600 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
0.990 |
|
Book Value (p.s.)
|
2.410 |
|
PEG Ratio
|
3.20 |
|
Profit Margin
|
13.80 |
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
7.0 |
|
Return on Equity (ttm)
|
46.4 |
|
Qtrly Rev. Growth
|
16.0 |
|
Gross Profit (p.s.)
|
8.478 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
9.40 |
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
P/E
|
44.94 |
|
P/E Growth Ratio
|
|
|
P/BV
|
18.46 |
|
P/S
|
|
|
P/CF
|
|
Dividends & Splits |
|
Dividend
|
1.060 |
|
Dividend Yield
|
0.02 |
|
Dividend Pay Date
|
2020-01-09 |
|
Ex-Dividend Date
|
2019-11-14 |
|
Forward Dividend
|
1.960 |
|
Last Split Date
|
|
|
Last Split Ratio
|
-1e+010 |
|
7 Binary Options
|
|
Your Ad Here
|
|
